TY - JOUR
T1 - Prevalence and impact of respiratory symptoms in a population of patients with COPD in Latin America: The LASSYC observational study
AU - Miravitlles, Marc
AU - Menezes, Ana
AU - López Varela, Maria Victorina
AU - Casas, Alejandro
AU - Ugalde, Luis
AU - Ramirez-Venegas, Alejandra
AU - Mendoza, Laura
AU - López, Ana
AU - Wehrmeister, Fernando C.
AU - Surmont, Filip
AU - Montes de Oca, Maria
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2018/1
Y1 - 2018/1
N2 - Background To analyse the relationship between symptoms at different times during the 24-hour day and outcomes in COPD. Methods Observational cross-sectional study in a patients from 7 Latin American countries. The frequency of symptoms in the morning, at night and during the day was explored by means of standardised and validated questionnaires, and the relationship between symptoms and exacerbations and quality of life were investigated. Results 734 patients (59.6% male, mean age 69.5 years, mean FEV1 50% predicted normal) were recruited. The most frequent symptoms during the day were dyspnea (75% of patients, of which 94% mild-moderate) and cough (72.2%, of which 93.4% mild-moderate). Highly symptomatic patients had a greater impairment in FEV1, more exacerbations and worse scores in COPD assessment test (CAT) and Body Mass Index, Obstruction, Dyspnoea and Exacerbations (BODEx) index (all p < 0.001). Morning symptoms were more frequent than night-time symptoms, particularly cough and dyspnoea (morning: 50.1% and 45.7%; night-time: 33.2% and 24.4%, respectively), and mostly rated as mild or moderate. Patients with morning or night-time symptoms presented with worse severity of daytime symptoms. There was a strong correlation between intensity of daytime with morning or night-time symptoms, as well as with CAT score (r = 0.715; p < 0.001), but a weak correlation with FEV1 (r = −0.205; p < 0.001). Conclusion Morning symptoms were more frequent than night-time symptoms, and having either morning and/or night-time symptoms was associated with worse severity of daytime symptoms. Increased symptoms were strongly associated with worse quality of life and more frequent exacerbations, but weakly associated with airflow limitation. Clinical trial registration NCT02789540.
AB - Background To analyse the relationship between symptoms at different times during the 24-hour day and outcomes in COPD. Methods Observational cross-sectional study in a patients from 7 Latin American countries. The frequency of symptoms in the morning, at night and during the day was explored by means of standardised and validated questionnaires, and the relationship between symptoms and exacerbations and quality of life were investigated. Results 734 patients (59.6% male, mean age 69.5 years, mean FEV1 50% predicted normal) were recruited. The most frequent symptoms during the day were dyspnea (75% of patients, of which 94% mild-moderate) and cough (72.2%, of which 93.4% mild-moderate). Highly symptomatic patients had a greater impairment in FEV1, more exacerbations and worse scores in COPD assessment test (CAT) and Body Mass Index, Obstruction, Dyspnoea and Exacerbations (BODEx) index (all p < 0.001). Morning symptoms were more frequent than night-time symptoms, particularly cough and dyspnoea (morning: 50.1% and 45.7%; night-time: 33.2% and 24.4%, respectively), and mostly rated as mild or moderate. Patients with morning or night-time symptoms presented with worse severity of daytime symptoms. There was a strong correlation between intensity of daytime with morning or night-time symptoms, as well as with CAT score (r = 0.715; p < 0.001), but a weak correlation with FEV1 (r = −0.205; p < 0.001). Conclusion Morning symptoms were more frequent than night-time symptoms, and having either morning and/or night-time symptoms was associated with worse severity of daytime symptoms. Increased symptoms were strongly associated with worse quality of life and more frequent exacerbations, but weakly associated with airflow limitation. Clinical trial registration NCT02789540.
UR - http://www.scopus.com/inward/record.url?scp=85036649638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85036649638&partnerID=8YFLogxK
U2 - 10.1016/j.rmed.2017.11.018
DO - 10.1016/j.rmed.2017.11.018
M3 - Research Article
C2 - 29413510
AN - SCOPUS:85036649638
SN - 0954-6111
VL - 134
SP - 62
EP - 69
JO - Respiratory Medicine
JF - Respiratory Medicine
ER -